Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	4.69B
Revenue (ttm)	238.34M
Net Income (ttm)	-384.75M
Shares Out	561.33M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,376,164
Average Volume	9,142,990
Open	8.80
Previous Close	8.88
Day's Range	8.33 - 8.90
52-Week Range	4.71 - 8.99
Beta	0.67
RSI	55.98
Earnings Date	Aug 22, 2025

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III cl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 391
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2024, Jiangsu Yahong Meditech's revenue was 201.56 million, an increase of 1365.55% compared to the previous year's 13.75 million. Losses were -384.06 million, -4.09% less than in 2023.